Form 8-K - Current report:
SEC Accession No. 0001193125-26-210298
Filing Date
2026-05-07
Accepted
2026-05-07 07:05:23
Documents
12
Period of Report
2026-05-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K glue-20260507.htm   iXBRL 8-K 54980
2 EX-99.1 glue-ex99_1.htm EX-99.1 230246
3 GRAPHIC img106802192_0.jpg GRAPHIC 12665
4 GRAPHIC img106802192_1.jpg GRAPHIC 12665
  Complete submission text file 0001193125-26-210298.txt   453240

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT glue-20260507.xsd EX-101.SCH 30669
15 EXTRACTED XBRL INSTANCE DOCUMENT glue-20260507_htm.xml XML 4892
Mailing Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118
Business Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40522 | Film No.: 26950803
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)